Holen Sie sich die Stockscreener-App
10.46
2.79%
-0.30
Handel nachbörslich:
10.46
Schlusskurs vom Vortag:
$10.76
Offen:
$10.81
24-Stunden-Volumen:
317.49K
Relative Volume:
0.37
Marktkapitalisierung:
$581.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-161.15M
KGV:
-2.8157
EPS:
-3.7149
Netto-Cashflow:
$-138.61M
1W Leistung:
-4.21%
1M Leistung:
-16.59%
6M Leistung:
-42.34%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.39
$10.87
1-Wochen-Bereich:
$10.13
$11.28
52-Wochen-Spanne:
$9.10
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
650-839-4360
Adresse
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
10.46 | 581.32M | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Needham | Buy |
| 2026-04-07 | Eingeleitet | TD Cowen | Buy |
| 2026-03-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Alle ansehen
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
MapLight stock falls 46% as InvestingPro Fair Value flagged overvaluation By Investing.com - Investing.com
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - Stocktwits
MapLight Therapeutics, Inc.(NasdaqGS:MPLT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
IPO Databook: MapLight Therapeutics (MPLT US)Sep 2026 - Smartkarma
MapLight Therapeutics (MPLT) General Counsel Kristopher Hanson Sells 16,509 Shares - gurufocus.com
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MapLight Therapeutics (MPLT) exec to sell shares under preset trading plan - Stock Titan
MapLight Therapeutics (MPLT) Edges Lower to $11.85, Testing Support Near $11.26Long Term Entry Picks - dars.gov.et
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.8%Here's Why - MarketBeat
MapLight Therapeutics, Inc. (MPLT) Stock Price Quote Today & Current Price Chart - Capital.com
MapLight Therapeutics to Participate in Upcoming Investor Conference - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against MapLight Therapeutics, Inc. (MPLT) and Encourages Stockholders to Learn More About the Investigation - accessnewswire.com
Raymond James initiates coverage on MapLight Therapeutics with Strong Buy - scanx.trade
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading Up 5.3%Here's What Happened - MarketBeat
Needham cuts MapLight Therapeutics price target on dilution concerns By Investing.com - Investing.com Canada
Maplight Therapeutics (NASDAQ:MPLT) Price Target Lowered to $43.00 at Needham & Company LLC - MarketBeat
MapLight Therapeutics (MPLT) Edges Higher to $12.60 as Traders Eye Key Resistance at $13.23PCR Moving Average - careplusvn.com
Freestone Grove Partners LP Makes New $6.05 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
5AM Venture Management LLC Makes New Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading Down 4.6%What's Next? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading 7.8% HigherShould You Buy? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study - Business Wire
Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
MPLT: MapLight Therapeutics, Inc.Financial Overview - Zacks Investment Research
MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7%Should You Sell? - MarketBeat
MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs - Stock Titan
MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan
MapLight Therapeutics (MPLT) grants CSO new options and RSUs - Stock Titan
MapLight (MPLT) Reported Results Review: The EPS Result Is Below Expectation in the Reported Period; Trading-Day Reaction: Shares Rise 5.11% in Latest TradingGuidance Downgrade Alert - Vinanet
Catalyst4 builds 49.9% MapLight (MPLT) stake in private share deal - Stock Titan
MPLT Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss of -$1.34 Per ShareROE Trend Analysis - careplusvn.com
MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Therapeutics announces $150M private placement - TipRanks
Morgan Stanley Maintains MapLight Therapeutics(MPLT.US) With Hold Rating, Maintains Target Price $21 - Moomoo
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
LifeSci Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20 - Moomoo
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta - Endpoints News
MapLight Therapeutics Announces $150 Million Private Placement Financing - marketscreener.com
MapLight bags USD 150m after muscarinic schizophrenia Phase II win - AllSci
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Cut to $28.77, Implies 148% Upside - TradingView
Dividend HistoryMapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Reports Positive Phase 2 Schizophrenia Data, Plans Phase 3 Trial - Minichart
Needham raises MapLight Therapeutics price target to $45 - scanx.trade
MapLight Q2 Results: Net loss widens to $60.2M, cash runway extends to 2028 - scanx.trade
MapLight Therapeutics Secures $150 Million Through Private Stock Placement - Kalkine Media
MapLight Therapeutics Announces Q2 2026 Financial Results with Rising Losses and R&D Expenses - Kalkine Media
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):